Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure Biosciences chief bullish on sale of new PreEMT platform

'In our wildest dreams, we didn't think we'd be securing such an important contract so soon,' said CEO Richard Schumacher
Two test tubes
Hundreds of labs already utilize the company's pressure-based systems to extract proteins from cells

Richard Schumacher, president and chief executive of Pressure BioSciences Inc. (OTCQB:PBIO), is extremely enthusiastic about the first contract the group has signed to sell its PreEMT platform and expects more deals to follow.

The Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

“In our wildest dreams, we didn’t think we’d be securing such an important contract so soon after the acquisition,” Schumacher noted in an interview held as part of the “Stock Day” podcast. “We view this as both significant and exciting and believe that additional contracts will soon be secured.”

In addition to the recent contract reached with the biopharma company, two other protein-based biotherapeutic companies have approached Pressure Biosciences in the last several weeks to ask about potential collaborations with similar studies.

READ: Pressure BioSciences expects BaroFold Inc to have "significant" impact on revenues in 2018

PreEMT technology improves the quality of manufacturing biopharma products and decreases manufacturing costs by as much as US$2mln to US$10mln per year for each commercial biologic drug.

Hundreds of labs already utilize Pressure Bioscience's pressure-based systems – which take advantage of pressure cycling technology – to extract proteins from all types of cells, whether it be plant, animal or human and whether the cells are normal or cancerous.

Pressure Biosciences has developed three new lab instruments that will be released within the next year and Schumacher is bullish about the company’s outlook for the year. “We are very excited about the potential of 2018 – we see this year shaping up well,” he said on the “Stock Day” podcast.

Pressure Biosciences shares closed up 5.7% to US$3.70 on Wednesday.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use